Glucocorticoid toxicity reduction with mepolizumab using the Glucocorticoid Toxicity Index

BACKGROUND: Reduction in glucocorticoid exposure is the primary benefit of new biologic treatments in severe asthma, but there is currently no evidence that reduction in glucocorticoid exposure corresponds to a proportionate reduction in associated toxicity. OBJECTIVES: To use the validated Glucocor...

Descripción completa

Detalles Bibliográficos
Autores principales: McDowell, P. Jane, Stone, John H., Zhang, Yuqing, Honeyford, Kirsty, Dunn, Louise, Logan, R. Jayne, McGarvey, Lorcan P.A., Butler, Claire A., Heaney, Liam G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770919/
https://www.ncbi.nlm.nih.gov/pubmed/34210787
http://dx.doi.org/10.1183/13993003.00160-2021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770919/
https://www.ncbi.nlm.nih.gov/pubmed/34210787
http://dx.doi.org/10.1183/13993003.00160-2021

Ejemplares similares